Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients. Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia. Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases. We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.
Location: United Kingdom, England, London
Employees: 501-1000
Total raised: $67.6M
Founded date: 1963
Investors 1
Date | Name | Website |
- | Nordic Cap... | nordiccapi... |
Funding Rounds 1
Date | Series | Amount | Investors |
10.03.2014 | - | $67.6M | - |
Mentions in press and media 2
Date | Title | Description |
21.08.2024 | Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption | New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outrea... |
01.06.2021 | ADVANZ PHARMA : Nordic Capital Acquires Specialty Pharmaceutical Company ADVANZ PHARMA in Deal Worth ~$846 Million | The acquisition will bring significant investment and expertise to help fuel ADVANZ PHARMA's growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to crit... |